Pfizer Innovent Oncology Deal | Lucid Diligence Brief
Pfizer Innovent Oncology Deal tests China-originated ADC and multi-specific…
Lucid Diligence Brief: Olema OP-3136 and Bayer Darolutamide Deal
Lucid Diligence Brief: Olema expands OP-3136 into metastatic…
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay Raises SERENA-6…
Lucid Diligence Brief: SELLAS REGAL AML Phase 3 Nears Final Analysis
Lucid Diligence Brief: SELLAS approaches REGAL AML final analysis for…
Lucid Diligence Brief: Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Lucid Diligence Brief: Incyte and Genesis Molecular AI expand collaboration…
Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049
Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…
Lucid Diligence Brief: Regeneron collaboration with Parabilis Medicines
Lucid Diligence Brief: Regeneron collaboration with Parabilis Medicines…
Vaccines Today—May 8, 2026
This weekly update in vaccines and immunotherapy covers recent developments…
Public Health Today—May 8, 2026
This weekly update in public health and biomedicine highlights emerging…
Public Health Today—May 1, 2026
This is a weekly update in public health, highlighting advances across clinical…
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration…
Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics
Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics Professional…